87 stories
Semaglutide is the active ingredient in Ozempic and Wegovy. Novo Nordisk holds the patent in most markets through 2031, but the Indian patent expired in March 2026 and a wave of generics from Biocon, Dr. Reddy's, and others followed within weeks.
The cardiovascular and renal evidence has expanded fastest. SELECT showed a 20% reduction in MACE for non-diabetic adults with obesity. The REMODEL trial (presented at the World Congress of Nephrology 2026) showed direct kidney protection independent of weight loss. Cell Metabolism work from Sinai Health pinned MASH reversal to liver sinusoidal endothelial cells, not weight loss or appetite. JAMA published a 90,000-patient HFpEF analysis showing a 42% reduction in heart-failure hospitalization or all-cause mortality.
The compounding story keeps moving in parallel. The FDA proposed excluding semaglutide from the 503B bulks list on April 30, 2026, with public comment open through June 29. Tirzepatide and liraglutide were folded into the same proposal.
Researchers analyzed 410,198 Reddit posts mentioning semaglutide or tirzepatide, finding 43.5% of 67,008 self-reported users described at least one side effect extending beyond clinical trial data.
Semaglutide injections officially removed from the FDA drug shortage list, though localized availability issues persist. Tirzepatide shortage status remains contested by the Outsourcing Facilities Association.
A large GWAS study published in Nature identified a missense variant in GLP1R predicting an additional 0.76 kg of weight loss per allele copy. GIPR variation was linked to nausea/vomiting side effects specific to tirzepatide users.
Tirzepatide (Mounjaro) Indian sales fell to ₹114 crore in March from ₹135 crore in February, while semaglutide sales rose to ₹59 crore. Semaglutide's GLP-1 segment share jumped to 33% from 25% as dozens of generics flood the market.
Research in JAMA Network Open shows semaglutide, tirzepatide, and bariatric surgery all produce substantial fat mass reduction but also cause reductions in lean mass over 24 months, highlighting the body composition tradeoff in GLP-1 treatment.
An indirect comparison found oral semaglutide may produce greater weight loss than orforglipron, though head-to-head T2D data showed orforglipron had greater HbA1c reductions vs lower-dose oral semaglutide. Lack of CV outcomes data for orforglipron remains a key limitation.
Based on analysis of 107,910 patients, the FDA concluded there is no increased suicide risk associated with GLP-1 medications and has requested removal of related warning labels.
Three months into its launch, oral Wegovy has driven explosive prescription demand, largely attracting new patients who avoided injections. Early data suggest the pill is expanding the obesity market rather than cannibalizing injectable users.
The FLOW trial showed semaglutide reduced major kidney events by 24%, and retatrutide demonstrated up to 28.7% weight loss in TRIUMPH-4. The full pipeline including CagriSema, MariTide, and survodutide was presented.
Comprehensive review examining GLP-1 receptor agonists for neurological conditions. A recent NEJM trial showed GLP-1 treatment resulted in less motor disability progression at 12 months.
Amazon Pharmacy expanded access to the new oral Wegovy pill with both insurance and cash-pay options, signaling a broader retail push to capitalize on surging oral GLP-1 demand.
Injectable semaglutide and tirzepatide will drop to ~$350/month initially and $245/month within two years, down from current list prices of $1,000–$1,350/month.
The ACHIEVE-3 trial in The Lancet showed Eli Lilly's Foundayo (orforglipron) superior on HbA1c, while Novo Nordisk's oral Wegovy may have an edge in weight-loss efficacy.
Phase IIIb results show investigational 7.2 mg semaglutide dose produced 21% mean weight loss in adults with obesity without diabetes, with a tolerable safety profile.
Industry analysis highlights CagriSema (cagrilintide + semaglutide) Phase 3 data showing 14.2% weight loss in type 2 diabetes adults, positioning it as a major Novo Nordisk pipeline asset.
Psychiatric Times provides educational review of the incretin system covering the shift toward oral nonpeptide small-molecule GLP-1 RAs and triple agonists expected within 1-2 years.
Analysis covers Novo's competitive positioning including ORION study results comparing oral semaglutide against orforglipron, plus up to 48% price cuts in India.
WeightWatchers began offering oral Wegovy with promotional pricing. Clinical trials showed 13.6% body weight loss with oral formulation versus 14.9% injectable.